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Ethanol-induced liver injury is a complex process dependent upon the interaction of multiple cell types
in the liver, as well as activation of the innate immune response. Increased expression of CYP2E1 in
response to high concentrations of ethanol leads to greater production of cytotoxic ethanol metabolites,
which in turn contribute to production of reactive oxygen species, oxidative stress, and ultimately, cell
death. Necroptotic hepatocyte cell death in response to ethanol is mediated via a CYP2E1-dependent
expression of receptor-interacting protein kinase 3 (RIP3), a key component of the necroptosome. In
response to alarmins released during ethanol-induced necroptosis, the innate immune response is
activated. Macrophage migration inhibitory factor (MIF), a pro-inﬂammatory multikine involved in many
disease processes, is an essential component to this response to injury. MIF expression is increased
during ethanol exposure via a CYP2E1-dependent pathway, likely contributing to an exacerbated innate
immune response and chronic inﬂammation after chronic ethanol. This review will discuss the complex
interactions between CYP2E1-dependent expression of RIP3 and MIF in the pathophysiology of chronic
ethanol-induced liver injury.
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search Institute/NE40, 9500Overview: alcoholic liver disease
Long-term excessive alcohol consumption can lead to alcoholic
liver disease (ALD) [1]. Heavy alcohol consumption is considered
40–80 g/day for males and 20–40 g/day for females; developmentnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. Dynamic interactions between parenchymal and non-parenchymal cells in
the liver during the progression of ALD. Parenchymal cells/hepatocytes carry out
the primary metabolic functions of the liver. One particularly important function of
hepatocytes is to metabolize ethanol. In the context of chronic ethanol exposure,
expression of CYP2E1 is increased in hepatocytes and Kupffer cells. Ethanol
metabolism via this pathway increases redox stress within the liver, resulting in
a condition of “organelle stress” whereby the hepatocytes exhibit impaired
metabolic function. Although hepatocytes are the most abundant cell type in the
liver, normal physiologic function depends on interaction between hepatocytes and
non-parenchymal cells (NPCs). NPCs include liver sinusoidal endothelial cells,
natural killer cells, natural killer T cells, and Kupffer cells, the liver resident
macrophage. Kupffer cells are an important site for the production of inﬂammatory
mediators, such as TNFα, during ethanol exposure. Kupffer cells and hepatocytes
are also important sources of chemokines, such as MCP-1 and MIF, which serve to
recruit peripheral leukocytes to the liver in response to hepatocellular injury and
inﬂammation.
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extended period of time, usually years [2]. ALD is one of the
leading causes of preventable death and accounts for approxi-
mately 4% of global mortality [3]. Clinical manifestations of ALD
patients include hepatic steatosis, steatohepatitis, liver ﬁbrosis,
cirrhosis, and hepatocellular carcinoma. The majority of chronic,
heavy drinkers develop steatosis, which is characterized by accu-
mulation of triglyceride droplets in the liver. However, this initial
stage of ALD is usually symptomless and reversible if the person
reduces alcohol intake [4]. However, further consumption of
alcohol may lead to the progression of liver disease. The develop-
ment of steatohepatitis, characterized by inﬁltration of leukocytes
into the liver, may occur at any stage of ALD and has a high risk of
mortality.
The progression of ALD involves direct effects of ethanol on
hepatocytes, resulting in hepatocellular injury and death, as wellas indirect effects of ethanol on innate immune pathways active in
the liver (Fig. 1). Innate immune signaling is activated in response
to bacterial derived signals, termed pathogen-associated molecu-
lar patterns (PAMPs), such as lipopolysaccharide (LPS), and dan-
ger-associated molecular patterns (DAMPs), which serve as alar-
mins that indicate the presence of cellular injury and debris. Un-
resolved activation of innate immune pathways then contributes
to the acceleration of hepatocellular injury, with an eventual loss
of hepatic function. Understanding the molecular and cellular
mechanisms linking ethanol metabolism to hepatocellular injury
and death to dysregulated innate immune activity is of critical
importance for developing rationally-designed therapeutic inter-
ventions to prevent and treat ALD. Here we will provide an
overview of one such pathway linking ethanol metabolism to a
speciﬁc pathway of cytochrome P4502E1 (CYP2E1)-dependent,
RIP3-mediated necroptotic cell death and subsequent activation
of innate immune signaling via the chemokine/cytokine macro-
phage inhibitory factor (MIF) that contributes to the progression of
ALD.Ethanol metabolism
Ethanol is metabolized in the liver parenchymal cells, hepato-
cytes, primarily in the area near the central vein [5]. Alcohol
dehydrogenase metabolizes ethanol to acetaldehyde, and subse-
quently, acetaldehyde is converted to acetate via acetaldehyde
dehydrogenase. Ethanol is also metabolized by cytochrome P450
2E1 (CYP2E1) to acetaldehyde; CYP2E1 expression is induced in
response to high concentrations of ethanol. Hepatocytes are the
primary site of CYP2E1 expression; however, CYP2E1 is induced in
Kupffer cells, the resident macrophage in the liver, in response to
chronic, heavy ethanol consumption (Fig. 1) [6]. Acetaldehyde is a
highly reactive aldehyde; therefore, production of this metabolite
can lead to oxidation of lipids and nucleic acids, as well as the
formation of protein adducts. Additionally, ethanol metabolism via
CYP2E1 leads to the generation of reactive oxygen species (ROS)
[2,7]. The resultant oxidative stress has multiple deleterious effects
on hepatocytes, including dysregulation of fatty acid synthesis and
oxidation, changes in the turnover of macromolecules, as well as
mitochondrial dysfunction and cellular stress, which can lead to
hepatocyte death [8,9].Mechanisms of ethanol-induced hepatocyte death
Multiple mechanisms of cell injury are associated with hepa-
tocyte death during progression of ALD (Fig. 2). Apoptosis, or
programmed cell death, is implicated as one of the major modes of
cell injury in the liver during ALD. Apoptosis is a caspase-
dependent cell death mechanism, mediated by two distinct path-
ways called the extrinsic (death-receptor-mediated) or the intrin-
sic (mitochondria-mediated) pathway [10]. In addition to apopto-
sis, non-apoptotic cell death pathways, including necrosis, are
implicated in ethanol-induced liver injury; however, little is
known about the molecular mechanisms of alcohol-induced
necrosis [11].
Recently, another mode of non-apoptotic cell death, necropto-
sis, has been characterized in a variety of cell types [12] and
implicated in the development of chronic ethanol-induced liver
injury in mice [13]. Necroptosis, like apoptosis, is a highly
regulated pathway of cell death; however, morphologically, the
process resembles necrosis. Exposure to death ligands, including
TNFα or CD95, initiates necroptotic signaling cascades that are
initially similar to pathways initiating apoptosis; however, the
metabolic status of the cell determines the subsequent steps of cell
Fig. 2. Mechanisms of cell death. Three potential pathways of hepatocellular cell
death are illustrated: apoptosis, necrosis and necroptosis. Apoptosis is character-
ized by cell shrinking and blebbing, as well as fragmentation of the nucleus and
DNA. Apoptosis proceeds under regulation from mitochondria and/or receptor
signaling, particularly the receptors for TNFα and Fas. Apoptosis is considered to be
the least inﬂammatory mode of cell death, as there is little release of cellular
contents (DAMPs) that would activate inﬂammatory and chemotactic responses.
Necrotic cell death is due to acute injury; cells swell and burst, leading to a release
of cytoplasmic contents into the extracellular space. These DAMPs trigger pathways
termed sterile inﬂammation that can lead to further hepatocellular injury [41]. MIF,
which is present in pre-formed pools in cells, can also be released by necrotic cells,
likely contributing to the sterile inﬂammatory response evoked by necrotic cells.
Necroptosis, or programmed necrosis, morphologically resembles necrosis; how-
ever, it is RIP3-mediated process and has been indicated as a mediator of ethanol-
induced liver injury in mice [13].
Fig. 3. Ethanol-induced necroptosis is RIP3-dependent. (A) In a healthy hepatocyte,
under physiologic conditions, TNFα-activated signaling is cytoprotective. TNF
receptor activation results in the activation NFκB, which promotes cell survival.
Cell survival is also promoted by TNFα-mediated inhibition of p53-dependent
apoptosis and induction of anti-apoptotic Bcl-2 family of proteins. In contrast,
under conditions of cellular stress, such as during chronic ethanol exposure, there
is a shift in the cellular response to TNFα from cytoprotection to cell death. Initially,
this response shift to apoptosis, the less inﬂammatory mode of cell death. However,
when expression of CYP2E1 is increased, there is an induction of RIP3, as well as
loss of mitochondrial integrity. This combination likely shifts the mode of cell death
to the more inﬂammatory necroptotic pathway. This shift in hepatocyte response to
TNFα, coupled with an increase in TNFα expression in the liver, leads to an increase
in RIP3-mediated cell death [13]. This shift in the continuum of hepatocellular
response to TNFα results in a switch from TNFα being cell protective to cell killing,
ﬁrst to the less inﬂammatory mode of apoptosis, but ultimately to the more
injurious necroptotic mode of cell death (B).
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apoptosis is inhibited, exposure to the Fas ligand or TNFα can even
exacerbate cell death via necroptosis. Receptor-interacting protein
(RIP) kinases, in particular RIP3, are key activators of necroptosis
(Fig. 3). RIP3, an inducible protein, is implicated in TNFα-induced
non-apoptotic cell death in a variety of cell types [14,15]. RIP3 has
a receptor homotypic interacting motif (RHIM) domain at its
C-terminus that mediates interaction with RIP1, while the N-term-
inal domain contains the kinase activity [12]. Interaction of RIP1
with the RHIM-containing C-terminal domain of RIP3 initiates
signals necessary for execution of necroptosis [15]. Under certain
conditions, RIP3 can also execute TNFα-induced cell death in a
RIP1-independent manner [16].
Chronic exposure to ethanol in mice increases the expression of
RIP3 in hepatocytes and RIP3 expression is increased in the livers
of patients with alcoholic liver disease [13]. While the mechanisms
for the induction of RIP3 in response to chronic, heavy ethanol
exposure are not well understood, importantly, this induction is
dependent on the expression of CYP2E1. Taken together, these data
link ethanol metabolism in the liver to RIP3-dependent cell death
(Fig. 3). This shift to the more injurious/pro-inﬂammatory pathway
of RIP3-mediated necroptosis contributes to the exacerbation of
chronic inﬂammation in the liver during ethanol exposure.Innate immune responses in alcoholic liver disease
The liver acts an important innate and adaptive immune organ
with a broad range of actions, involving both cellular and soluble
factors. This complex, dynamic organ houses a large population of
natural killer, natural killer T cells and Kupffer cells (Fig. 1). The
liver is also the principal site of production of complement
proteins, as well as other molecules important for orchestrating
an immune response [17]. Many cells types contribute to ALD
pathogenesis and the essential role of Kupffer cell activation and
sensitization in ALD has been well characterized [4] (Fig. 1).
In addition to contribution of the cellular components of the
innate immune system to ALD, soluble innate immune factors
have been identiﬁed as key factors in the progression of ALD. The
role of soluble mediators, particularly pro-inﬂammatory cytokines
[18], in early progression of ALD has been well documented.
However, additional innate immune mediators, e.g. complement
anaphylatoxins and chemokines, also contribute to promotion of
the pathogenesis of ALD, but are much less understood.Cytokines and alcoholic liver disease
A variety of cytokines are upregulated in the liver in response
to ethanol exposure; in particular, TNFα is a critical mediator of
ALD. TNFα is produced by many cells types; however, in the liver it
is primarily produced by Kupffer cells [19]. TNFα production is an
Fig. 4. MIF signaling. (1) MIF is stored in intracellular pools in unstimulated cells, associated with Golgi-associated protein p115. (2) Upon stimulation of a cell, a macrophage
in this illustration, MIF is released into the extracellular environment, where is dissociates from p115. MIF can act in a paracrine, endocrine or autocrine fashion. (3) Once it
reaches its target cell, MIF engages its cognate receptor complex, CD74–CXCR2/4. To date, only CD74, also known as major histocompatibility class II (MHC II) invariant chain,
has been identiﬁed as a cognate receptor for MIF. As a part of the MHC II antigen presenting complex, the invariant chain prevents MHC II from binding proteins in the
endoplasmic reticulum (ER) and acts as a protein chaperone in the ER. Though most CD74 is associated with MHC II, a small proportion of protein is located at the cell
surface, where it is expressed as a transmembrane protein. (4) Interaction with the receptor complex initiates intracellular signaling events, including MAP kinase signal
transduction. CD74’s short cytoplasmic tail is not believed to possess direct signaling capacity; instead CD74 forms signaling complexes with CD44 and chemokine receptors
CXCR2/4 [42]. CD44 is a multifunctional surface protein that acts as a receptor for ECM proteins and is involved with leukocyte activation. CD74 alone was able to bind MIF;
however, activation of MAP kinase signaling required association and phosphorylation of CD44 to the signaling complex. Additionally, MIF signaling activates MAP kinases
via interaction with CXCR4 [43]. CD74–CXCR4 complex is also important for endocytosis of MIF and subsequent intracellular signaling [44]. (5) Once MIF-dependent MAP
kinase signaling is activated numerous cellular responses are possible, including production of cytokines and other pro-inﬂammatory mediators, such as TNFα and TLR4, and
adhesion molecules, as well as inhibition of p53-dependent apoptosis. MIF can also lead to sustained MAP kinases signaling, which is usually transient [45,46]. Much less is
known about the direct chemotactic properties of MIF, but they are likely linked to its ability to bind CXCR2/4. Interaction between MIF and CXCR2/4 mediates monocyte
chemotaxis by promoting expression of integrins that assist in cell migration, arrest and extravasation [47].
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Furthermore, LPS–TLR-4 signaling, which leads to production of
TNFα, is important for development of ALD [20]. Ethanol exhibits a
sensitizing effect on monocytes, as monocytes from patients with
ALD, as well as rodents after heavy, chronic ethanol exposure,
produce increased amounts of TNFα in response to LPS challenge
compared to monocytes from healthy individuals [18,21]. IL-1β is
an another potent pro-inﬂammatory mediator and is elevated in
patients with ALD, as well as in animal models after heavy, chronic
ethanol exposure [22]. Clinical trials are currently underway to test
the efﬁcacy of IL1 receptor antagonists (Anakinra) in the treatment
of alcoholic hepatitis [23].Complement and alcoholic liver disease
Complement is an important mediator of innate and adaptive
immune responses. Complement proteins exhibit opsonizing,
chemotactic and cell lytic properties. In the context of ALD,
complement components C1q, C3, and C5 are known to contribute
to the progression of ethanol-induced liver injury in mice [24,25].Chemokines and alcoholic liver disease
While the role of cytokines in ALD, particularly TNFα, has been
extensively studied, the role of chemokines is not well understood.Chemokines are a subset of cytokines that specialize in recruit-
ment of cells during homeostasis and inﬂammation through
chemotaxis, movement of cells toward a chemical signal or
gradient [26]. Mandrekar et al. explored the role of MCP-1
(CCL2), a potent chemoattractant for monocytes, in ethanol-
induced liver injury. Ethanol feeding to mice increased MCP-1 in
both Kupffer cells and hepatocytes. Increased expression of MCP-1
was associated with increased liver injury, as well as, increased
expression of pro-inﬂammatory mediators. Additionally, MCP-1
promotes hepatic triglyceride accumulation by inhibiting action of
peroxisome proliferator-activated receptor-α (PPAR-α), a protein
to protein that promotes oxidation of fatty acids [27]. This was the
ﬁrst study to establish a role for chemokines in promoting liver
injury, and surprisingly, promoting hepatic steatosis.Macrophage migration inhibitory factor (MIF)
Macrophage migration inhibitory factor (MIF) is a soluble
factor, initially described as a T cell-derived mediator that inhib-
ited movement of macrophages, which is involved in many disease
processes [28–30]. Since its original discovery, MIF has been
shown to be a multipotent innate immune mediator that is
involved in many diseases, including multiple liver diseases [31].
Although MIF is known to contribute to ALD [32], its precise role
(s) in the progression of ALD is still under continued investigation.
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Determining the exact cellular source of MIF under speciﬁc
pathophysiological conditions has remained elusive because there
are many sources of MIF. MIF is released by many cell types
including macrophages, which are considered a major source of
MIF, other leukocytes, endothelial cells, epithelial cells, as well as
the pituitary gland. It is likely that multiple cells types contribute
to increased MIF in the systemic circulation [31,33].
One of the ﬁrst described functions of MIF was its ability to inhibit
glucocorticoid (GC) action. GCs exhibit potent anti-inﬂammatory
properties, such suppression of inﬂammation and leukocyte recruit-
ment. Because MIF is induced by glucocorticoids and acts as a negative
regulator to glucocorticoid mediated responses, it helps maintain
normal immune function despite increases in anti-inﬂammatory
signals. One method GCs utilize to reduce inﬂammation involves
activating MAP kinase phosphatase (MKP). MKPs dephosphorylate
MAP kinases, which are essential signaling proteins during immune
responses, thus inactivating them and suppressing pro-inﬂammatory
immune functions [34]. MIF counteracts GCs by activating MAP kinase
signaling and promoting leukocyte recruitment [35,36].MIF and alcoholic liver disease
Expression of MIF in liver is increased in patients with alcoholic
hepatitis or cirrhosis, with expression increased in both hepatocytesFig. 5. The role of MIF in ethanol-induced liver injury. (1) Ethanol exposure leads to activ
Studies modeling chronic ethanol feeding to mice have revealed that ethanol exposure in
in the circulation. MIF production appears to be dependent on CYP2E1-mediated ethan
chronic ethanol feeding compared to wild-type mice, suggesting that induction of M
exposure may be related to localized hypoxia in the liver during ethanol metabolism [48,4
is associated with increased serum MIF, as well as increased expression of MIF mRNA an
Taken together, it is likely that ethanol metabolism via CYP2E1, in conjunction with loca
during chronic ethanol feeding. (3) Activated Kupffer cells and MIF contribute to increase
and recruits peripheral monocytes to the liver. MIF is involved in both the early and ch
recruitment of inﬁltrating monocytes after chronic ethanol feeding [37]. During ethanol-
fashion. These observations indicate that MIF directly, and/or indirectly via MCP-1, rec
happens ﬁrst, but a complex feedback loop is formed between inﬁltrating monocytes
increased pro-inﬂammatory mediators in the liver leads to death of hepatocytes.and monocytes. Further, circulating concentrations of MIF are corre-
lated with plasma aspartate aminotransferase in patients with alco-
holic hepatitis or cirrhosis [32].
The underlying mechanisms by which ethanol promotes ex-
pression and release of MIF are likely complex, but it is clear that
this response is at least partially dependent on CYP2E1 [37]. While
regulation of MIF expression and secretion is not well understood,
recent studies have provided insights into possible mechanisms of
control. One mechanism involves microRNA-451 directly interact-
ing with the 3′ UTR of MIF and regulates MIF expression. Golgi-
Associated Protein p115 was shown to be essential for releasing
MIF from cytoplasmic pools (Fig. 4). When p115 was depleted in
human monocytes, cells exhibited reduced ability to release MIF
into the extracellular environment [38]. Cells stimulated with LPS
in vitro secreted both MIF and p115 into their supernatant, further
demonstrating the association between MIF and p115 in the
control of MIF secretion [39].Summary
Hepatocellular injury in response to chronic ethanol exposure
is dependent on expression and activity of CYP2E1. Metabolism of
ethanol via this pathway is associated with a shift in the mode of
hepatocyte cell death in response to inﬂammatory mediators, from
the relatively homeostatic pathway of apoptosis to the more
injurious pathway of necroptosis (Fig. 3). Multiple DAMPs areation of Kupffer cells. (2) Ethanol exposure also leads to increased expression of MIF.
creased the expression of MIF mRNA in the liver, as well as the concentration of MIF
ol metabolism. CYP2E1/ mice do not induce the expression of MIF mRNA after
IF is CYP2E1 dependent. Another contributor to induction of MIF during ethanol
9]. Ischemia–reperfusion, which similar to ethanol exposure, results in hypoxia and
d protein [50]. MIF also enhances its own expression under hypoxic conditions [48].
lized ethanol-induced hypoxia in the liver, contributes to increased MIF expression
d production of pro-inﬂammatory mediators. MIF additionally acts as a chemokine
ronic innate immune responses in the liver after ethanol feeding and is critical for
induced liver injury, expression of MCP-1 mRNA was increased in a MIF-dependent
ruits monocytes from peripheral immune reservoirs. (4) It is not yet clear which
and pro-inﬂammatory mediators. Ethanol-mediated inﬁltration of monocytes and
M.A. Barnes et al. / Redox Biology 2 (2014) 929–935934released from necroptotic hepatocytes, and as a result, there are
multiple innate immune pathways activated to respond to this
injury.
One key pathway activated in response to ethanol-induced
injury is MIF. MIF has been implicated in the pathogenesis of many
inﬂammatory diseases including sepsis, colitis, metabolic disor-
ders, and multiple types of arthritis [31]. MIF is an important for
modulation of expression of pro-inﬂammatory mediators, includ-
ing TNFα, IFNγ, IL-1β, TLR4, and is produced by and exerts its
effects upon many different cells types, including directly promot-
ing chemotaxis (Fig. 5). MIF contributes to the progression of
ethanol-induced liver injury at multiple stages in the pathophy-
siology of ALD and ASH. The primary role of MIF is associated with
regulation of expression of pro-inﬂammatory and chemotactic
mediators, and recruitment of peripheral monocytes. MIF contri-
butes to the pathophysiology of ethanol-induced liver injury in
mice and suggest that inhibition of MIF activity with small
molecule inhibitors of MIF, such as ISO-1 [40], may be an
important therapeutic approach to the treatment of ALD.Acknowledgements
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